US · biotech · hyperphosphatemia · kidney disease
Who invested in R1 Therapeutics
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
1
rounds observed
6
investors named
$78M
reported across those rounds
Mar 2026
most recent
The rounds
Series A · Mar 2026 · $78M
F-Prime lead, Abingworth lead, DaVita Venture Group lead, SymBiosis, Curie.Bio, U.S. Renal Care
Reported by TechStartups
Everyone who backed them
InvestorTypeRounds
Missing a round, or an investor who was in one? Tell us.